PEANUT ALLERGY STUDY

Registry ID

EUCTR2016-005004-26

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Aimmune Therapeutics, Inc.

Start date

2017-03-13

Completion date

2019-02-15

Last update

2026-08-16

Conditions

• Peanut Allergy
• Peanut allergy.

Summary

The primary objective is to demonstrate the efficacy of AR101, a pharmaceutical-grade peanut allergen formulation, through reduction in clinical reactivity to limited amounts of peanut allergen in peanut-allergic children and adolescents (ages 4 to 17 years, inclusive).

Locations

• , , Italy
• , , France
• , , Ireland
• , , UK
• , , Sweden
• , , Spain
• , , Germany

Related clinical trials

• Safety of MOON101 for the Treatment of Peanut Allergy
• Efficacy of Tezepelumab in Peanut Oral Immunotherapy
• UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
• Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety
• Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
• Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

View on source registry